Market Access Views & Analysis

Views & Analysis

Patients

Hand flips a block changing 2021 to 2022. New year beginning. Holidays and Christmas. Trends and changes in the World. Summing work done. Build plans. New normal. Keep up with everything planned.

2021 in review: Building the framework of a patient-centric ...

Patient centricity and patient engagement have been hot topics in pharma for some time – but buzz words do not always translate into concrete action.

Oncology

Regulation optimisation could save thousands of life years

Embracing a “once-in-a-generation opportunity” to improve access to oncology treatments could save thousands of years of life across the European Union.

Market Access

Post-Brexit medicines regulation must have international sco...

Post-pandemic, post-Brexit Britain must create a regulatory framework that both defines and aligns with international standards, or risk being left behind.

Market Access

Innovation and collaboration - the MHRA’s pandemic approach

The pandemic has propelled issues for the pharmaceutical industry to the top of the political and public agenda, from clinical trial recruitment to the journey required for medicines or vac

Market Access

Are we measuring what matters most on uptake to medicines in...

In the second of a two-part series, Leela Barham argues that whilst international comparisons of uptake are useful, there could be more to gain from looking at more medicines and their upta

Market Access